Course Overview
Mitigating the Risk of Chemotherapy-Associated Cardiotoxicity in Breast Cancer
Overview: This multi-module Webcast includes a 30-minute didactic presentation, two 30-minute case studies, and a 30-minute expert discussion. The didactic module reviews the mechanisms for the development of chemotherapy-related cardiotoxicity in patients with breast cancer, analyzes the propensity for various chemotherapeutic agents to cause cardiotoxicity, and discusses patient- and drug-related risk factors. Case 1 focuses on assessing the risk of cardiotoxicity from anthracycline or trastuzumab-based regimens and reviewing guideline-based recommendations for the coordination of care between oncologists and cardiologists. Case 2 focuses on strategies for continued management and monitoring of cardiac function in patients with breast cancer who develop heart failure. In the expert discussion, faculty analyze available clinical trial evidence for medications approved for the treatment of chemotherapy-based cardiotoxicity and discuss critical management issues and best practice recommendations.
Faculty
Michael S. Ewer, MD, MPH, JD
Special Assistant to the VP for Medical Affairs
Professor of Medicine, Cardiology
University of Texas MD Anderson Cancer Center
Houston, TX
Sandra M. Swain, MD
Medical Director, Washington Cancer Institute
Washington Hospital Center
Professor of Medicine
Georgetown University
Washington, DC
William J. Gradishar, MD
Director of Breast Oncology
Program Director, Hematology-Oncology Fellowship Training Program
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Credits available: A maximum of 2.0 AMA PRA Category 1 Credits™
Types of credit available:
AMA PRA Category 1 Credit™
Expires: 4/20/11
This activity has been approved for AMA PRA Category 1 Credit™
Supported by an educational grant from:
Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.
Bookmark These Med-IQ Sites
Med-IQ Specialty Sites
